Американское общество гирудотерапии

Bell's Palsy (Acute Idiopathic Facial Paralysis)

Investigational adjunct in acute idiopathic facial nerve palsy; case-series suggest faster House-Brackmann recovery as add-on to corticosteroids.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?
Not FDA-cleared for Bell's palsy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for Bell's palsy is investigational.
Какие доказательства существуют?
Tier C (investigational). Small case reports describe facial recovery timelines with adjunctive leech therapy. There are no randomized controlled trials in Bell's palsy. Spontaneous recovery is high (about 70-85%) which complicates interpretation of uncontrolled reports. Evidence-based first-line therapy is high-dose oral corticosteroids started within 72 hours of symptom onset (NNT ~10), with consideration of antivirals in severe cases; physical therapy / facial-rehabilitation exercises also help.
Основные риски
  • Bleeding from bite sites for 6 to 24 hours after detachment (placement on the face)
  • Bruising and tenderness on visible facial skin for 5 to 10 days
  • Itching and irritation at bite sites
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Small permanent facial scars at bite sites — cosmetically significant
  • Delayed presentation to neurology if used in place of evidence-based steroid therapy, missing the 72-hour window
Кому не следует это рассматривать
  • Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with severe anemia (Hb <10 g/dL)
  • Patients considering this INSTEAD OF oral corticosteroids within the 72-hour window
  • Patients with atypical features (bilateral, slowly progressive, other neurologic signs) — needs urgent neurology workup
  • Patients with active herpes zoster (Ramsay Hunt syndrome) or Lyme disease (treat the cause)
  • Patients with a weakened immune system
О чём спросить врача
  • Have I been seen by a neurologist or ENT promptly to confirm Bell's palsy and rule out other causes (stroke, Ramsay Hunt, Lyme)?
  • Have I started oral corticosteroids within the 72-hour window?
  • Has eye-protection been arranged (lubrication, taping, eye patch) to prevent corneal injury?
  • What evidence supports leech therapy for Bell's palsy specifically?
  • Will leeches be kept away from the eye and lid?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost?
Когда срочно обратиться за медицинской помощью
  • Sudden facial weakness with other neurologic symptoms — arm/leg weakness, speech difficulty, vision change (possible stroke — call 911)
  • Bilateral facial weakness, progressive weakness over days, or rash with painful blisters in or around the ear (Ramsay Hunt)
  • Severe eye pain, redness, or vision change (corneal injury from inability to close the eye)
  • Spreading redness, warmth, pus, or red streaks on the face (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

Что это НЕ означает

  • This is not FDA-cleared for Bell's palsy.
  • High spontaneous-recovery rate (70-85%) means uncontrolled case reports cannot establish efficacy.
  • Mechanism rationale (local anti-inflammation around the facial nerve) does NOT establish clinical efficacy.
  • Leech therapy is NOT a substitute for early oral corticosteroids in the 72-hour window.
  • Facial leech application carries cosmetic risk and proximity to eye/ear structures.

Перекрёстные ссылки безопасности

Clinical Profile

Category
neurological
ICD-10
G51.0
Safety tier
medium

Evidence Summary

Bell's palsy spontaneous recovery rates exceed 70% with early high-dose corticosteroids per AAN/AAO-HNS 2013 guidelines. No controlled clinical trial or published case series of leech therapy for Bell's palsy or facial paralysis exists; any use is investigational and mechanistic only, with a proposed but unproven mechanism of perineurial edema reduction at the stylomastoid foramen. Evidence grade is D. Standard care (prednisone 60 mg/day × 7-10 days, eye protection, antiviral co-therapy initiated within 72 hours) remains primary.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Singh S et al. (2017), n=24

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Ramsay Hunt syndrome (herpes zoster) — antiviral therapy primary
  • Suspected stroke or central lesion (image first)
  • Otitis media or external ear infection

Related Conditions

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.

Bell's Palsy (Acute Idiopathic Facial Paralysis) — Hirudotherapy Evidence | ASH